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DISTRIBUTION DE LA DOXORUBICINE LIBRE ET LIPOSOMALE APRES 
PERFUSION ISOLEE DU POUMON DANS UN MODELE SARCOMATEUX 
Introduction 
La perfusion isolée du poumon à l'aide de Doxorubicine libre et une nouvelle forme de 
Doxorubicine liposomale pégylée (Liporubicine) est comparé en terme de pénétration et 
accumulation de Doxorubicine dans le tissu tumoral et pulmonaire dans un modèle de rats porteurs 
de tumeur sarcomateuse au niveau du poumon gauche. 
Matériel et méthode 
Une tumeur sarcomateuse unique a été générée dans le poumon gauche de 39 Fischer rats, suivi 10 
jours plus tard, par une perfusion isolée du poumon gauche (n =36) avec Doxorubicine libre (n=18) 
et Liporubicine (n=18) à une dose de 100 µg (n=9) et 400 µg (n=9) pour chaque formulation de 
Doxorubicine. Dans chaque poumon perfusé, la concentration de l'agent cytostatique et sa 
distribution ont été investiguées dans la tumeur et trois parties du poumon normal par HLPC (n=6) 
et par microscopie de florescence (n=3). Des analyses histologiques et immunohistochimiques 
(facteur von Willebrand) ont été effectuées sur trois animaux non traités. 
Résultats 
Les tumeurs sarcomateuses dans les animaux de contrôle démontraient une bonne vascularisation 
avec de fines branches capillaires qui étaient présentes partout dans les tumeurs. La perfusion isolée 
du poumon démontrait une distribution de l'agent cytostatique d'une manière hétérogène dans le 
poumon perfusé et une concentration de Doxorubicine inférieure dans les tumeurs par rapport au 
tissu pulmonaire sein pour les deux formulations de Doxorubicine et les deux doses appliquées. La 
perfusion isolée du poumon avec Doxorubicine libre démontrait une concentration 
significativement plus élevée que Liporubicine dans la tumeur et le parenchyme pulmonaire pour 
les deux doses appliquées (p < 0,01). Néanmoins, le coefficient de concentration tumorale et 
pulmonaire était plus bas pour Doxorubicine libre que pour Liporubicine pour une dose de 100 µg 
(0.27 ± 0.1 vs 0.53 ± 0.5, p=0.23) tandis qu'il était similaire pour les deux formulations de 
Doxorubicine à une dose de 400 µg (0.67 ± 0.2 vs 0.54 ± 0.2, p=0.34). Les deux formulations de 
Doxorubicine émergeaient un signal de fluorescence provenant de tous les compartiments du 
parenchyme pulmonaire mais seulement un signal sporadique et faible émergeant des tumeurs, 
provenant de la périphérie de la tumeur et des vaisseaux situés à l'intérieur de la tumeur, pour les 
deux doses appliquées. 
Conclusion 
La perfusion isolée du poumon démontrait une distribution hétérogène de la Doxorubicine et sa 
forme liposomale dans le poumon perfusé et une accumulation plus faible dans la tumeur que dans 
le tissu parenchymateux adjacent pour les deux formulations de Doxorubicine et les deux doses 
appliquées. 
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Baclcgro11nd. Isolated lung perfusion (ILP) with free 
and a novel liposomal-encapsulated doxorubicin (Lipo-
rubicin, CT Sciences SA, Lausanne, Switzerland) was 
compared with respect to drug uptake and distribution in 
rat lungs bearing a sarcomatous tumor. 
Methods. A single sarcomatous tumor was generated in 
the left lung of 39 Fischer rats, followed 10 days later by 
left-sided ILP (n = 36) with free and equimolar-dosed 
liposomal doxorubicin at doses of 100 µg (n = 9) and 400 
µg (n = 9) for each doxorubicin formulation. In each 
perfused lung, the drug concentration and distribution 
were assessed in the tumor and in three areas of normal 
lung parenchyma by high-performance liquid chroma-
tography (n = 6) and fluorescence microscopy (n = 3). 
Histologie assessment and immunostaining with von 
Willebrand factor was performed in 3 animais with 
untreated tumors. 
Res11lts. The sarcomatous tumors in controls were well 
vascularized with fine branching capillaries present 
throughout the tumors. Isolated lung perfusion resulted 
in a heterogeneous drug distribution within the perfused 
lung and a consistently lower drug uptake in tumors than 
I solated lung perfusion (ILP) of cytostatic drugs has been assessed under clinical [1-8] and experimental 
[9-15] conditions for various agents, including doxorubi-
cin [1-3, 10-14, 16] , melphalan [8], platinum [4, 7], and 
tumor necrosis factor-a (TNF-a) combined with interfer-
on-'Y [5]. It allows for a targeted delivery of the drug to the 
lung with an up to sevenfold higher drug concentration 
in lung tissue. Plasma levels after ILP are significantly 
lower compared with intravenous application of the 
cytostatic drug [13, 14]. Under clinical conditions, how-
ever, ILP has failed to demonstrate a relevant antitumor 
activity, irrespective of the cytostatic agent administered 
[1-5, 7]. 
Doxorubicin, an active anthracycline against sarcoma, 
has been extensively tested in ILP [15]. Doxorubicin-
based ILP in sarcoma-bearing rats resulted in a high drug 
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in lung parenchyma for both doxorubicin formulations 
and both drug doses applied. Isolated lung perfusion 
with free doxorubicin resulted in a significantly higher 
drug uptake than Liporubicin in both the tumor and lung 
tissue for both drug doses applied (p < 0.01). However, 
the tumor/normal tissue drug ratio was lower for free 
than for liposomal doxorubicin at a drug dose of 100 µg 
(0.27 ± 0.1 vs 0.53 ± 0.5; p = 0.225) and similar for both 
doxorubicin formulations at a drug dose of 400 µg (0.67 ± 
0.2 vs 0.54 ± 0.2; p = 0.335). Both doxorubicin formula-
tions resulted in fluorescence signaling emerging from 
all tissue compartments of normal lung parenchyma but 
only in weak and sporadic signaling from the tumors 
confined to the tumor periphery and vessels situated 
within the tumor for both drug doses assessed. 
Conclusions. Isolated lung perfusion with free and 
liposomal doxorubicin resulted in a heterogeneous drug 
distribution within the perfused lung and in a lower 
drug uptake in tumors than in lung tissue for both 
doxorubicin formulations and drug doses applied. 
(Ann Thorac Surg 2008;85:1225-32) 
© 2008 by The Society of Thoracic Surgeons 
uptake in lung tissue, minimal systemic toxicity, and 
measurable antitumor activity [10-12]. However, clinical 
studies suggest a lower drug uptake in tumors than in the 
surrounding normal lung tissue after doxorubicin-based 
ILP [1-3]. In addition, experimental doxorubicin-based 
ILP in a porcine model has shown a heterogeneous 
pattern of drug distribution within the perfused lung 
despite a high overall lung drug uptake [16]. 
Liporubicin (CT Sciences SA, Lausanne, Switzerland) 
is a newly developed pegylated, liposomal-encapsulated 
formulation of doxorubicin. Liposomal-encapsulated 
drugs have been shown to evade the immune system, 
and their surface features promote increased permeabil-
ity of the tumor vasculature for these compounds, lead-
ing to a preferential accumulation within tumor tissues 
[17-20]. We hypothesized that Liporubicin-based ILP 
may result in a better tumor drug uptake and in an 
enhanced ratio of tumor/normal lung tissue concentra-
tion compared with free doxorubicin. For this purpose, 
ILP with two doses of free doxorubicin and equimolar-
dosed Liporubicin were compared in a sarcoma model 
0003-4975/08/$34.00 
doi:10.1016/j.athoracsur.2007.12.028 
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with respect to the concentration and distribution of the 
cytostatic agent in the tumor and normal lung tissue. 
Material and Methods 
Shtdy Design 
Single-pass gravity-driven antegrade ILP of the left lung 
was performed in 39 animals bearing a sarcoma tumor in 
their left lung that was generated by a subpleural injec-
tion of a sarcoma cell suspension 10 days before ILP, as 
previously described [21]. Nine animals were perfused 
with 100 µg doxorubicin and 9 with an equimolar dose of 
Liporubicin; 9 animals were perfused with 400 µg doxo-
rubicin and 9 with an equimolar dose of Liporubicin. 
Sixty minutes after restoration of the pulmonary circula-
tion, the animals were sacrificed and the perfused lungs 
were harvested. The doxorubicin concentration and dis-
tribution in the tumor and surrounding lung were as-
sessed by high-performance liquid chromatography 
(HPLC) in 6 animals of each group and by fluorescence 
microscopy for 3 animals of each group. The tumors of 3 
untreated animals underwent histologie assessment and 
immunostaining with von Willebrand factor to assess 
their vascularization. 
Animals and Housing 
Male Fischer 344 rats, weighing 250 to 300 g (Charles 
River, L' Arbresle, France) were used. They had free 
access to standard laboratory rat chow and water and 
were housed with a 12:12 hour light-dark circle under 
controlled temperature. They were treated in accordance 
with the Animal Welfare Act, the National Institutes of 
Health Guidelines for the Care and Use of Laboratory Ani-
mals, and according to the Local Ethical Committee of the 
University of Lausanne. 
Tumor Cell Line 
A syngeneic methylcholanthrene-induced sarcoma 
(MCA) cell line kindly supplied by the Memorial Sloan-
Kettering Cancer Center (New York, NY) was used. The 
MCA cell line was cultivated at 37°C and 5% carbon 
dioxide in 20 mL of Roswell Park Memorial Institute 
(RPMI)-1640 medium containing glutaryl, 10% fetal bo-
vine serum (FBS), and 1 % penicillin/streptomycin (In-
vitrogen Corp, GIBCO Life Technologies Ltd, Paisley, 
United Kingdom). For the preparation of the cell suspen-
sion, the cells were washed twice with phosphate-
buffered saline (PBS) and detached with 4 mL of trypsin. 
Tumor cell vitality was assessed in a hematocytometer 
after centrifugation at 1000g for 4 minutes, washing, 
resuspension in PBS, and addition of trypan blue. The 
cell suspension was adjusted to a density of 5.0 X 107 vital 
cells/mL. 
Generation of Sarcoma Tumors Within the Left Lung 
Anesthesia was induced by an intraperitoneal injection of 
pentobarbital sodium (50 mg/kg) and 0.1 % atropine (0.05 
mL/kg). Orotracheal intubation was performed by tra-
cheal insertion of a 16-gauge polyethylene angiocatheter 
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(Becton Dickinson, Sandy, UT) using a laryngoscope. The 
catheter was connected to a standard rodent ventilator 
(Model 683, Harvard Apparatus Inc, Les Ulis, France) and 
ventilation was performed with a mixture of oxygen and 
0.5% to 2% isoflurane (Forene, Abbott, Baar, Switzer-
land). A tidal volume of 10 mL/kg was adjusted with a 
respiratory rate of 75 to 90 breaths/min. A small left-
sided thoracotomy was performed through the seventh 
intercostal space, and 0.1 mL of MCA cell solution con-
taining 5.0 X 106 viable tumor cells were injected sub-
pleural into the left lower lobe by use of a 27-gauge 
needle and a 0.3-mL insulin syringe [21]. The thoracot-
omy was closed in layers, and the endotracheal tube was 
removed after spontaneous breathing of the animais. 
Antegrade Isolated Perfusion of the Left 
Tumor-Bearing Lung 
Ten days after tumor implantation, single-pass antegrade 
ILP was performed in 36 animais. Eighteen animals 
were perfused with doxorubicin (Adriblastin, Pharma-
cia & Upjohn, Dübendorf, Switzerland) and 18 with 
Liporubicin. 
The animals were anesthetized as described. A left-
sided thoracotomy was performed through the fourth 
intercostal space. An operative microscope was used 
(original magnification X16; Carl Zeiss, Jena, Germany). 
The inferior pulmonary ligament was divided, and the 
left lung was retracted anteriorly. The mediastinal pleura 
were opened, and the left phrenic nerve was preserved. 
The left pulmonary artery and vein were dissected. The 
vessels were encircled with 8-0 Prolene (Ethicon, Somer-
ville, NJ) suture and clamped. Small transverse incisions 
were performed in the PA and PV distal to the clamps 
using microvascular scissors, and both vessels were can-
nulated by use of 2 catheters consisting of a 2-cm poly-
ethylene tube (0.10 mm internal diameter, 0.30 mm outer 
diameter) connected to 20-cm polyethylene tube (0.30 
mm internal diameter, 0.60 mm outer diameter; Clinical 
Plastic Products SA, La Chaux-de-Fonds, Switzerland). 
Single-pass antegrade ILP with doxorubicin or 
equimolar dosed Liporubicin dissolved in 5 mL of 6% 
hydroxyethyl starch (HAES; Intramed, Woodmead, 
Sandton, South Africa), was performed for 20 minutes 
using a roller pump at a flow-rate of 0.25 mL/min. 
Antegrade ILP consisted of drug administration through 
the pulmonary artery and effluent collection from the 
pulmonary vein. 
The cytostatic perfusion was followed by a washout 
phase of the perfused isolated lung for 10 minutes with 5 
mL of 6% HAES at the same perfusion conditions. The 
lung was ventilated during ILP with a positive end-
expiratory pressure (PEEP) of 2 to 3 cm H20. After 
completion of ILP, the catheters were removed, and the 
vessels were repaired by interrupted transverse sutures 
using 10-0 Prolene, followed by declamping and restora-
tion of the circulation. Ventilation with a PEEP of 2 to 3 
cm H20 was continued for 60 minutes after restoration of 
the circulation. At this point, the animais were sacrificed 
and the perfused lung was harvested. 
Ann Thorac Surg 
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Assessment of Doxorubicin Concentration in Tumor 
and Lung Tissues 
After the lungs were harvested, the tumor nodule was 
dissected from the surrounding normal lung tissue by 
use of the operation microscope, and tumor and normal 
tissue of the perfused lung were analyzed separately. 
After dissection and excision of the tumor, the tumor-free 
perfused lung tissue was eut in 3 pieces corresponding to 
the upper, middle, and lower part of the lung. The 
samples were stored at -80°C before analysis. Doxoru-
bicin concerttration measurements in the tumor and 
lung tissues were performed by HPLC as previously 
described [22]. For Liporubicin concentration measure-
ments, the technique has been adjusted for the release 
of doxorubicin from liposomes, in accordance with 
Chin and colleagues [23]. 
The concentrations of doxorubicin in tissues were 
separately determined in the upper, middle, and lower 
part of the tumor-free parenchyma of each perfused lung 
to assess the spatial drug distribution within the perfused 
lung. Coefficients of variation were calculated from these 
three values for each perfused lung as previously 
described [16]. 
Assessment of Drug Distribution by Fluorescence 
Microscopy 
The perfused lungs were harvested, snap frozen in liquid 
nitrogen by contact with isopentane slush, stored at 
-70°C, and processed for fluorescence microscopy as 
previously described [24]. The frozen tissue blacks were 
mounted in optimal cutting temperature medium (Tis-
sue-Tek II embedding compound, Sakura Finetek Eu-
rope B.V., Zoeterwoude, the Netherlands) and a series of 
sections was eut with a cryomicrotome (Frigocut Model 
2700, Reichert, Switzerland.). 
Six consecutive, nonstained 5-µ,m-thick tissue sections 
mounted on clean glass slides were prepared for each 
sample. From each frozen section, three images were 
recorded over three different parts of the slice to avoid 
photo bleaching. We used a Zeiss AxioPlan-2 microscope 
equipped with a Zeiss Axiophot image analysis system 
(Carl Zeiss) and a filtered 100-W mercury lamp as exci-
tation light source. Images were recorded with a grey-
scale camera with a 12-bits dynamic range and 2 X 2 
binning, resulting in 694- X 520-pixel images with 4095 
grey levels. A filter "cube" (set 40012, Chroma Technol-
ogy Corp, Rockingham, VT; excitation: HQ 480/40x, di-
chotic mirror: Q505LP) and a barrier filter (HQ510LP) 
have been used for epifluorescence measurements. 
After recording the fluorescence images, the same 
slices were stained with hematoxylin and eosin. A hema-
toxylin and eosin image was recorded from the identical 
position and compared with the fluorescence image to 
determine the histologie localization of doxorubicin us-
ing the public domain ImageJ 1.31 program (National 
Institutes of Health, Bethesda, MD) [25]. This technique 
allows the detection of the fluorescence signaling of 
doxorubicin in different tissue compartments of normal 
lung parenchyma and within the tumor. 
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Fig 1. Immttnostaining with von Willebrand factor of ttntreated sar-
coma tttmors reveals a well-circumscribed sarcomatous hmwr main/y 
formed by large undifferentiated cells with a vascular network con-
sisting of fine branching capillaries present througlwut the tunwr. 
Immunostaining highlights endothelial cells and the vascular bed in 
the htmors (original magnification X 400). 
Statistical Analysis 
Doxorubicin concentrations in tumors and normal lung 
parenchyma were compared for both doxorubicin formu-
lations using a Student t test for unrelated samples. 
Variabilities in doxorubicin lung tissue levels were ex-
pressed as the coefficients of variation of tissue concen-
tration in the three parts of perfused lungs for both 
doxorubicin formulations, and drug doses and were 
compared using the Student t test. A bidirectional hy-
pothesis was applied and significance accepted at p < 
0.05. 
Results 
Contrais 
Histologie assessment of 3 untreated tumors revealed a 
well-circumscribed sarcomatous tumor in each lung, 
mainly formed by large undifferentiated cells. Immuno-
staining by von Willebrand factor revealed an extensive 
vascular network composed of small vessels and capil-
laries present throughout the tumors (Fig 1). The tumor 
size ranged from 3 to 8 mm in diameter. The mitotic 
index ranged from 12 to more than 100 mitoses per 10 
high power fields (surface, 0.221 mm3 / field). Spontane-
ous necrosis was observed in less than 2% of the tumor 
volume for each case analyzed. No tumor growth within 
the pleural cavity was identified in any of the animais. 
Isolated Lung Perfusion 
Thirty-five animais underwent successful antegrade left 
ILP with doxorubicin and Liporubicin, respectively. One 
animal had to be excluded from concentration measure-
ments of free doxorubicin because of leakage and insuf-
ficient drug exposure of the lung during perfusion. 
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Assessment of Doxorubicin Concentration in Tumor 
and Lung Tissues 
After the lungs were harvested, the tumor nodule was 
dissected from the surrounding normal lung tissue by 
use of the operation microscope, and tumor and normal 
tissue of the perfused lung were analyzed separately. 
After dissection and excision of the tumor, the tumor-free 
perfused lung tissue was eut in 3 pieces corresponding to 
the upper, middle, and lower part of the lung. The 
samples were stored at -80°C before analysis. Doxoru-
bicin concentration measurements in the tumor and 
lung tissues were performed by HPLC as previously 
described [22]. For Liporubicin concentration measure-
ments, the technique has been adjusted for the release 
of doxorubicin from liposomes, in accordance with 
Chin and colleagues [23]. 
The concentrations of doxorubicin in tissues were 
separately determined in the upper, middle, and lower 
part of the tumor-free parenchyma of each perfused lung 
to assess the spatial drug distribution within the perfused 
lung. Coefficients of variation were calculated from these 
three values for each perfused lung as previously 
described [16]. 
Assessment of Drug Distribution by Fluorescence 
Microscopy 
The perfused lungs were harvested, snap frozen in liquid 
nitrogen by contact with isopentane slush, stored at 
-70°C, and processed for fluorescence microscopy as 
previously described [24]. The frozen tissue blocks were 
mounted in optimal cutting temperature medium (Tis-
sue-Tek II embedding compound, Sakura Finetek Eu-
rope B.V., Zoeterwoude, the Netherlands) and a series of 
sections was eut with a cryomicrotome (Frigocut Model 
2700, Reichert, Switzerland.). 
Six consecutive, nonstained 5-µm-thick tissue sections 
mounted on clean glass slides were prepared for each 
sample. From each frozen section, three images were 
recorded over three different parts of the slice to avoid 
photo bleaching. We used a Zeiss AxioPlan-2 microscope 
equipped with a Zeiss Axiophot image analysis system 
(Carl Zeiss) and a filtered 100-W mercury lamp as exci-
tation light source. Images were recorded with a grey-
scale camera with a 12-bits dynamic range and 2 X 2 
binning, resulting in 694- X 520-pixel images with 4095 
grey levels. A filter "cube" (set 40012, Chroma Technol-
ogy Corp, Rockingham, VT; excitation: HQ 480/40x, di-
chotic mirror: Q505LP) and a barrier filter (HQ510LP) 
have been used for epifluorescence measurements. 
After recording the fluorescence images, the same 
slices were stained with hematoxylin and eosin. A hema-
toxylin and eosin image was recorded from the identical 
position and compared with the fluorescence image to 
determine the histologie localization of doxorubicin us-
ing the public domain ImageJ 1.31 program (National 
Institutes of Health, Bethesda, MD) [25]. This technique 
allows the detection of the fluorescence signaling of 
doxorubicin in different tissue compartments of normal 
lung parenchyma and within the tumor. 
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Fig 1. Immunostaining with von Willebrand factor of untreated sar-
coma tumors reveals a well-circumscribed sarcomatous tumor mainly 
formed by large undifferentiated cells with a vascular network con-
sisting of fine branching capillaries present througlwut the tumor. 
Immunostaining highlights endothelial cells and the vascular bed in 
the tumors (original magnification X 400). 
Statistical Analysis 
Doxorubicin concentrations in tumors and normal lung 
parenchyma were compared for both doxorubicin formu-
lations using a Student t test for unrelated samples. 
Variabilities in doxorubicin lung tissue levels were ex-
pressed as the coefficients of variation of tissue concen-
tration in the three parts of perfused lungs for both 
doxorubicin formulations, and drug doses and were 
compared using the Student t test. A bidirectional hy-
pothesis was applied and significance accepted at p < 
0.05. 
Results 
Controls 
Histologie assessment of 3 untreated tumors revealed a 
well-circumscribed sarcomatous tumor in each lung, 
mainly formed by large undifferentiated cells. Immuno-
staining by von Willebrand factor revealed an extensive 
vascular network composed of small vessels and capil-
laries present throughout the tumors (Fig 1). The tumor 
size ranged from 3 to 8 mm in diameter. The mitotic 
index ranged from 12 to more than 100 mitoses per 10 
high power fields (surface, 0.221 mm3 / field). Spontane-
ous necrosis was observed in less than 2% of the tumor 
volume for each case analyzed. No tumor growth within 
the pleural cavity was identified in any of the animais. 
Isolated Lung Perfusion 
Thirty-five animais underwent successful antegrade left 
ILP with doxorubicin and Liporubicin, respectively. One 
animal had to be excluded from concentration measure-
ments of free doxorubicin because of leakage and insuf-
ficient drug exposure of the lung during perfusion. 
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Table 1. Results of Isolated Lung Perfusion With Free Doxorubicin and Equimolar-Dosed Liporubicin 
Result 
Tissue concentration• 
Lung, µg/g 
Tumor, µg/g 
Ratiob 
CV%c 
Drug Dose, 100 µg 
Free Doxorubicin 
13.8 ± 4.3 
3.9 ± 2.5 
0.27 ± 0.1 
27% 
Liporubicin 
2.0 ± 0.7 
0.8 ± 0.5 
0.53 ± 0.5 
49% 
Drug Dose, 400 µg 
Free Doxorubicin 
58.5 ± 20.1 
36.9 ± 10.4 
0.67 ± 0.2 
24% 
Liporubicin 
5.2 ± 3.7 
3.2 ± 3.5 
0.54 ± 0.2 
28% 
a These data are presented as the me an ± standard deviation. b Ratio of tumor/normal tissue drug concentrations. c CV is the coefficient of 
variation of doxorubicin levels measured in the upper, middle, and lower tumor-free part of the perfused lung. 
Doxorubicin Concentration in Ttunor and Normal 
Lung Parenchyma After Isolated Lung Perfusion 
Table 1 reports the drug concentrations in the tumor and 
lung parenchyma after ILP for both doxorubicin formu-
lations and both drug doses applied as well as the 
coefficient of variation (CV%) of drug tissue concentra-
tions in the upper, middle, and lower parts of the 
perfused lungs. 
Isolated lung perfusion led to a heterogeneous spatial 
drug distribution within the perfused lung for both 
doxorubicin formulations and both drug doses as dem-
onstrated by the large coefficients of variation. In addi-
tion, there was a wide interanimal variability of drug 
concentrations in the tumor and normal lung tissue for 
both doxorubicin formulations. 
FREE DOXORUBICIN. Increasing the administered dose from 
100 µ,g to 400 µ,g resulted in a fourfold increased drug 
Fig 2. Fluorescence microscopie 
assessment of the peifused ltmgs 
after isolated lung perfusion (ILI') 
at a drug dose of 100 µ,g. (A) Flu-
orescence plwtomicrograph and (B) 
corresponding hematoxylin and 
eosin, after doxorubicin-based ILP 
reveal weak and sporadic signal-
ing confined ta the tumor (T) pe-
riphery and surrounding lung pa-
renchyma (LP). (C) Fluorescence 
photomicrograph and (D) corre-
sponding hematoxylin and eosin 
stain, after Liporubicin-based ILP 
reveal weak and sporadic signaling 
confined ta the tumor periphen; and 
surrounding lung parenchyma (orig-
inal magnification X 40). 
uptake in lung tissue (13.8 vs 58.5 µ,g/g; p = 0.001) and in 
an approximately tenfold increased uptake in tumors (3.9 
vs 36.9 µ,g/g; p = 0.0001). Accordingly, this significantly 
improved the tumor/normal tissue drug ratio from 0.27 ± 
0.1 to 0.67 ± 0.2 (p = 0.003). However, the doxorubicin 
concentrations in tumors were always lower than in lung 
tissue for both drug doses and all animals assessed. 
LIPORUBICIN. Increasing the equimolar-dosed doxorubicin 
dose from 100 µ,g to 400 µ,g resulted in an almost 
threefold higher drug uptake in lung tissue (2.0 vs 5.2 
µ,g/g) and a fourfold higher uptake in tumors (0.8 vs 3.2 
µ,g/g). However, due to the large interanimal variability, 
this difference was not statistically significant. Both drug 
doses resulted in a similar tumor/normal tissue drug ratio 
of 0.53 ± 0.5 vs 0.54 ± 0.2 (p = 1.0). The drug concentrations 
were always lower in the tumor than in lung tissue for both 
drug doses and in all but 1 animal assessed. 
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COMPARISON OF FREE AND LIPOSOMAL DOXORUBICIN. Isolated 
lung perfusion with free doxorubicin resulted for bath 
drug doses in a significantly higher drug uptake in 
tumors and lung tissue than Liporubicin (p < 0.01). 
However, the tumor/normal tissue drug ratio was higher 
for Liporubicin than for free doxorubicin at a drug dose 
of 100 µg (0.53 ::':: 0.5 vs 0.27 ::':: 0.1; NS) and similar for bath 
doxorubicin formulations at a drug dose of 400 µg (0.54 ::':: 
0.2 vs 0.67 ::':: 0.2; NS). A higher dose of Liporubicin did 
therefore not result in an increase of the tumor/normal 
tissue drug ratio in contrast to what has been observed 
with free doxorubicin. 
At a drug dose of 100 µg, Liporubicin resulted in a 
more heterogeneous drug distribution than free doxoru-
bicin within the perfused lung (CV, 49% vs 27%; p = 0.03), 
whereas at 400 µg, the heterogenicity of drug distribution 
was similar for bath doxorubicin formulations (CV, 28% 
vs 24%). 
Doxorubicin Distribution in Tumor and Nonnal Lung 
Parenchyma After Isolated Lung Perfusion 
Fluorescence microscopy revealed fluorescence signaling 
exclusively confined to the nuclei of the cells of normal 
lung parenchyma and tumor tissue, whatever the tissue 
or cell type observed. This holds true for bath doxorubi-
cin formulations and was found in all perfused lungs. 
Fluorescence signaling after Liporubicin-based ILP was 
weaker than with free doxorubicin in all perfused lungs 
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Fig 3. Fluorescence microscopie 
assessment of the peifused lungs 
after isolated lung perfusion (ILP) 
at a drug dose of 400 µg. (A) A 
fluorescence plwtomicrograph and 
(B) a corresponding hematoxylin 
and eosin stain after doxorubicin-
based ILP reveal weak and spo-
radic signaling confined ta the 
tumor (T) periphery and 
surrounding lung parenchyma 
(LP). (C) A fluorescence photomi-
crograph and (D) corresponding 
hematoxylin and eosin stain after 
Liporubicin-based ILP reveal weak 
and sporadic signaling confined ta 
the tumor periphery and surround-
ing lung parenchyma (original 
magnification X 40). 
for bath drug doses applied. Bath doxorubicin formula-
tions resulted in fluorescence signaling emerging from all 
tissue compartments of normal lung parenchyma, in-
cluding pneumocytes of the alveolar wall, endothelial 
cells of blood vessels, branchial epithelium, and me-
sothelial cells covering the parietal pleura. In contrast, 
bath doxorubicin formulations resulted in weak and 
sporadic fluorescence signaling emerging from tumors, 
which was mainly confined to the tumor periphery, to 
peritumoral inflammatory cells, and to blood vessels 
situated within the tumor tissue, irrespective of the drug 
dose applied (Fig 2 and Fig 3). 
Comment 
Chemotherapy for sarcoma has been extensively studied, 
but unfortunately, the responsiveness of these tumors to 
chemotherapy has been disappointingly low. Doxorubi-
cin and ifosfamide remain the two only drugs that have 
consistently shown response rates ranging between 10% 
and 25%, and doxorubicin is in many centers considered 
the standard treatment for advanced soft tissue sarcoma. 
Because advanced soft tissue sarcoma often presents as 
lung metastases without extra thoracic tumor manifesta-
tion, doxorubicin-based ILP has been designed with the 
aim to increase drug uptake to the lungs while sparing 
the systemic circulation. Isolated lung perfusion has been 
explored in clinical and experimental settings and has 
1230 YAN ET AL 
DISTRIBUTION OF DOXORUBICIN 
demonstrated excellent separation between systemic and 
pulmonary circulations and effectively delivered high 
doses of the cytostatic agent to the perfused lung. The 
tumor response was modest in those clinical trials where 
no metastasectomy was performed, however, and several 
studies have demonstrated a lower drug uptake in the 
tumors than in normal lung parenchyma after ILP per-
formed under clinical and experimental circumstances 
[1,2,3,27]. Effective shielding of the tumor tissues from the 
delivered drug [26] or uneven drug distribution within 
the perfused lung [16,27] may be responsible for the 
disappointing results after ILP. 
This study was designed to assess whether ILP with 
liposomal-encapsulated doxorubicin resulted in a more 
homogeneous drug distribution in the perfused lung and 
a higher drug uptake in tumors compared with free 
doxorubicin. Liposomal delivery systems for anthracy-
clines have shown several advantages compared with the 
administration of the free drug. They have been investi-
gated for their ability to improve drug delivery to tumors 
while decreasing toxicity to normal tissues [17-20]. 
The tumor-targeting mechanism relies on the size of 
liposomes, which render them difficult to extravasate 
through the capillaries of normal tissues outside of the 
reticuloendothelial system. This suggests little exposure 
of normal tissues to the toxicity associated with doxoru-
bicin, in particular, a reduction of cardiac toxicity [17, 18]. 
In contrast, tumor angiogenesis results in discontinuous 
capillaries with gaps between capillary endothelial cells, 
which may facilitate extravasation, and accumulation of 
liposomes in tumor tissues [17, 18]. 
The rapid sequestration of liposomes by the reticu-
loendothelial system may be avoided by pegylation [19, 
20]. Liporubicin is a recently developed pegylated lipo-
somal doxorubicin. Passive targeting of pegylated lipo-
somes to solid tumors has been shown under clinical 
conditions for various malignancies [19, 20]. We hypoth-
esized that ILP with Liporubicin would render the treat-
m en t more tumor selective compared with free 
doxorubicin. 
We compared the distribution of free and equimolar-
dosed liposomal doxorubicin (Liporubicin) after ante-
grade ILP of rodent lungs containing a sarcomatous 
tumor. Doxorubicin-based IPL has been repeatedly ex-
plored in this experimental setting [9-12, 15, 27]. In 
addition to the clinical relevance of doxorubicin for the 
treatment of advanced sarcoma, the auto fluorescence 
properties of this agent allow its localization within 
tissues by use of fluorescence microscopy [27]. Two 
currently used drug dosages [11] were assessed for bath 
doxorubicin formulations using the same experimental 
setting as described in a previous study [27]. 
The tumors were generated by subpleural injection of 
the tumor cell suspension, and histologie assessment 
including immunostaining by von Willebrand factor re-
vealed a well-circumscribed sarcomatous tumor without 
spontaneous necrosis and a rich vascular network con-
sisting of fine branching capillaries. Von Willebrand 
factor is a highly specific but poorly sensitive marker for 
endothelial cells [28]. Hence, the visible vascular network 
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after von Willebrand immunostaining witnesses the 
presence of a well-developed and probably underesti-
mated tumor vascularization. 
Doxorubicin tissue concentration measurements re-
vealed a heterogeneous spatial drug distribution in the 
perfused lung and a wide interanimal variability of drug 
tissue concentrations within the tumor and normal lung 
parenchyma for bath doxorubicin formulations and drug 
dosages assessed. Bath drug formulations resulted in 
lower drug concentrations in the tumors than in lung 
parenchyma for bath drug dosages. Liporubicin-based 
ILP did obviously not result in a better tumor drug 
uptake compared with free doxorubicin in this model, for 
bath drug dosages applied. 
Isolated lung perfusion with free doxorubicin consis-
tently resulted in significantly higher drug concentra-
tions in tumors but also in normal lung tissues compared 
with equimolar-dosed Liporubicin for bath drug dosages 
applied. However, a high doxorubicin concentration in 
normal lung parenchyma theoretically also bears the risk 
of increased doxorubicin-induced lung toxicity. In con-
trast, ILP with Liporubicin resulted in a higher tumor/ 
normal tissue drug ratio than with free doxorubicin, but 
only at the lower drug dose assessed (100 µg). For the 
higher drug dose (400 µg), the tumor/normal lung tissue 
drug ratio was similar for bath drug formulations. A 
higher dose of Liporubicin did therefore not result in a 
better tumor/normal tissue drug ratio in contrast to what 
has been observed with free doxorubicin. We speculate 
that the exposure of the tumors to a higher dose of free 
doxorubicin during ILP may overcome the cellular drug 
expel mechanisms in this model. 
Isolated lung perfusion with a higher dose of Liporu-
bicin led to a more homogeneous drug distribution 
within the perfused lung compared to the lower drug 
dose. The variability in drug distribution in lung tissue 
was similar for bath doxorubicin formulations at a dose 
of 400 µg but was associated with a much lower lung 
tissue concentration for Liporubicin than free doxorubi-
cin. This may be an advantage with respect to clinical 
application because of doxorubicin-based lung toxicity 
[1-3, 13, 14]. 
Fluorescence microscopie assessment revealed for 
bath doxorubicin formulations at bath drug dosages a 
fluorescence signaling emerging from ail tissue compart-
ments of the perfused lungs. The signaling emerging 
from the tumors was only weak and sporadic, however, 
and was mainly confined to the tumor periphery and to 
the vessels situated within the tumors for bath drug 
formulations and irrespective of the drug dose applied. 
The fluorescence microscopie findings parallel the drug 
tissue concentration measurements with a consistently 
lower drug uptake in tumors than in normal lung paren-
chyma for bath doxorubicin formulations and drug doses 
applied. 
Our results suggest that doxorubicin-based ILP in this 
setting results in insufficient drug accumulation in the 
tumors, for bath doxorubicin formulations and bath drug 
doses applied. We speculate that the poor tumor drug 
uptake observed for bath doxorubicin formulations may 
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be related to tumor-inherent mechanisms [26]. Our re-
sults do not suggest that these results are related to a lack 
of tumor vascularization, because histologie and immu-
nohistochemical staining revealed a dense vascular net-
work present throughout the tumor and the absence of 
spontaneous tumor necrosis. 
A criticism of our experimental setting might address 
the relatively short exposure time of the perfused lung to 
the cytostatic agents. Nevertheless, the exposure time 
was sufficient to enable a significant drug uptake in the 
perfused lung in all animais assessed. Moreover, another 
in vivo study that assessed doxorubicin distribution in 
murine tumors by use of fluorescence microscopy after 
intravenous injection also demonstrated a lower drug up-
take in tumors than in surrounding normal tissues [29]. 
Another criticism may involve the route of sarcoma cell 
injection to the rodent lung in our model. Metastases in 
humans are presumed to be generated by blood-borne 
tumor cell seeding. In our model, the tumor was gener-
ated by direct subpleural injection of the tumor cell 
suspension, which may not reflect the clinical situation. 
In a previous study, we compared the generation of 
MCA-induced sarcoma in rodent lungs either by the 
intravenous or the subpleural route of tumor cell injec-
tion [21]. Both techniques resulted in tumors of similar 
histologie features and vascularization. The subpleural 
injection resulted in a more reliable and reproducible 
tumor growth of one single tumor but with a branchial 
artery-derived vasculature. Nevertheless, the compari-
son of antegrade and retrograde doxorubicin-based ILP 
in this model revealed a similar tumor drug uptake for 
both techniques, although one might theoretically expect 
a better tumor drug uptake after retrograde ILP, given 
the branchial artery-derived tumor vascularization [27]. 
In addition, the tumor drug uptake after ILP in our 
setting was comparable to that reported in other studies 
where the tumors were generated by intravenous cell 
injection. 
In conclusion, ILP with free doxorubicin resulted in a 
higher drug uptake in tumors and lung parenchyma than 
equimolar dosed liposomal doxorubicin for both drug 
doses applied. The tumor/normal tissue drug ratio was 
higher for liposomal doxorubicin at a lower drug dose 
and similar for both formulations at a higher drug dose. 
Both doxorubicin formulations resulted in a heteroge-
neous drug distribution in the perfused lung and in 
consistently lower drug uptake in tumor compared with 
lung parenchyma, irrespective of the drug dose applied. 
Future investigations must focus on means for enhanced 
and selective tumor uptake of cytostatic agents during 
isolated lung perfusion. 
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Requirements for Maintenance of Certification in 2008 
Diplomates of the American Board of Thoracic Surgery 
(ABTS) who plan to participate in the Maintenance of 
Certification (MOC) process which will begin in 2008 
must hold an unrestricted medical license in the locale of 
their practice and privileges in a hospital accredited by 
the JCAHO (or other organization recognized by the 
ABTS). In addition, a valid ABTS certificate is an absolu te 
requirement for entrance into the Maintenance of Certi-
fication process. If your certificate has expired, the only 
pathway for renewal of a certificate is to take and pass the 
Part I (written) and the Part II (oral) certifying examina-
tions. 
The names of individuals who have not maintained 
their certificate will no longer be published in the Amer-
ican Board of Medical Specialties directories. Diplo-
mates' names will be published upon successful comple-
tion of the Maintenance of Certification process. 
The CME requirements are 30 Category I credits 
earned during each year prior to application. At least half 
of these CME hours need to be in the broad area of 
thoracic surgery. Category II credits are not allowed. 
Interested individuals should refer to the Booklet of 
Information for Maintenance of Certification for a com-
plete description of acceptable CME credits. 
Diplomates in the Maintenance of Certification process 
will be required to complete all sections of the SESATS 
© 2008 by The Society of Thoracic Surgeons 
Published by Elsevier Inc 
self-assessment examination. lt is not necessary for Dip-
lomates to purchase SESATS individually because it will 
be sent to them after their application has been ap-
proved. 
Diplomates may apply for Maintenance of Certification 
in the year their certificate expires, or if they wish to do 
so, they may apply up to two years before it expires. 
However, the new certificate will be dated 10 years from 
the date of expiration of their original certificate or most 
recent recertification certificate. In other words, going 
through the Maintenance of Certification process early 
does not alter the 10-year validation. Diplomates certified 
prior to 1976 (the year that time-lirnited certificates were 
initiated) are also required to participate in MOC if they 
wish to maintain valid certificates. 
The deadline for submission of application for the 
Maintenance of Certification is May 10 of each year. Ali 
ABTS diplomates will receive a letter from the Board 
outlining their individual timeline and MOC require-
ments. A brochure outlining the rules and requirements 
for Maintenance of Certification in thoracic surgery is 
available upon request from the American Board of 
Thoracic Surgery, 633 North St. Clair St, Suite 2320, 
Chicago, IL 60611; telephone (312) 202-5900; fax (312) 
202-5960; e-mail: info@abts.org. This booklet is also pub-
lished on the website: www.abts.org. 
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